Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -59.27% | 774.80% | 35.07% | -89.20% | 104.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.27% | 774.80% | 35.07% | -89.20% | 104.25% |
| Cost of Revenue | -65.89% | -94.22% | -81.69% | -83.70% | -56.17% |
| Gross Profit | 66.98% | 99.62% | 85.39% | 79.40% | 84.72% |
| SG&A Expenses | -13.13% | -43.44% | -52.66% | -51.50% | 283.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.44% | -77.97% | -72.56% | -76.48% | -33.66% |
| Operating Income | 50.54% | 81.57% | 74.88% | 69.92% | 77.17% |
| Income Before Tax | -68.65% | 72.78% | 70.92% | 65.81% | 90.89% |
| Income Tax Expenses | -100.00% | -- | 67.26% | -71.43% | 101.14% |
| Earnings from Continuing Operations | -68.61% | 72.78% | 70.95% | 65.82% | 90.88% |
| Earnings from Discontinued Operations | -98.54% | 585.02% | -80.73% | 32.84% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.08% | 1,274.41% | 51.09% | 114.09% | 131.98% |
| EBIT | 50.54% | 81.57% | 74.88% | 69.92% | 77.17% |
| EBITDA | 49.92% | 81.77% | 74.93% | 70.09% | 77.11% |
| EPS Basic | -178.83% | 1,267.73% | 51.68% | 113.81% | 131.39% |
| Normalized Basic EPS | 49.52% | 78.19% | 72.10% | 66.73% | 76.57% |
| EPS Diluted | -178.83% | 1,267.73% | 51.68% | 113.81% | 131.39% |
| Normalized Diluted EPS | 49.52% | 78.19% | 72.10% | 66.73% | 76.57% |
| Average Basic Shares Outstanding | 0.32% | 0.57% | 1.23% | 1.99% | 3.63% |
| Average Diluted Shares Outstanding | 0.32% | 0.57% | 1.23% | 1.99% | 3.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |